Continued Access to HIV Treatment for People Finishing Earlier ViiV Healthcare Studies
Lets people with HIV keep taking study drugs after earlier ViiV studies end.
Key facts
- Who runs it
- ViiV Healthcare
- Where
- Durban, Gauteng, Johannesburg, and Jouberton, South AfricaSee the 4 sitesAlso in 2 other countries, 2 sites
- Trial code
- Registry title
- A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 197 people, planned
- Started
- 21 Jul 2026
- Expected to end
- 14 Sept 2032
- Type of study
- Interventional
- Treatments tested
- Fostemsavir
- Dolutegravir (DTG)/ Lamivudine (3TC)
- Record updated
- 13 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who finished a ViiV Healthcare HIV treatment study, still benefit from the study drug, and do not have local access to it.
- Sex
- All sexes can join.
- Earlier treatment
- Must have completed the treatment period of a ViiV Healthcare parent study and still be benefiting from that treatment.
Main reasons for not taking part
- Not meeting the parent study's stop or withdrawal criteria is required, so people who met them cannot join.
- Any reason the investigator or the sponsor decides rules a person out.
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Investigator confirmation of the participant's continued clinical benefit from the parent study intervention and the participant's completion of the protocol-defined treatment period in the parent study. The Investigator should ensure that the participant is still eligible for the parent study (i.e., have not met parent study discontinuation/ withdrawal criteria)
- Participants or legally authorized representative (LAR) who are willing and able to comply with all scheduled visits, treatment plan, and other study procedures as outlined in the applicable appendix and determined by the Investigator
- Participant or LAR is able and willing to provide signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and this protocol. Where applicable, participants must provide written assent
Who cannot take part
- Any reason that, in the opinion of the Investigator or Sponsor, precludes the participant's inclusion in the study
This trial is currently available in South Africa.
Also in 2 other countries, 2 sites
- DurbanHospital not named in the registryContact: Tiyara Arumugam (principal investigator)Taking people
- GautengHospital not named in the registryContact: Avy Violari (principal investigator)Taking people
- JohannesburgHospital not named in the registryContact: Faeezah Patel (principal investigator)Taking people
- Jouberton, MatlosanaHospital not named in the registryContact: Ebrahim Variava (principal investigator)Taking people
About the trial
What the trial wants to find out
The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.
The group in the trial
- Continued Access GroupTreatment being tested
Participants with HIV-1 who received the study intervention and completed the protocol-defined treatment period in ViiV Healthcare-sponsored or ViiV Healthcare-collaborative parent studies (2020-001029-30, 2020-001426-57), and who continue to receive the study intervention from their respective parent study.
Treatment: Fostemsavir and Dolutegravir (DTG)/ Lamivudine (3TC)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3b, Open-label, Multicenter, Continued Access Study for Participants Transitioning From ViiV Healthcare Sponsored or ViiV Healthcare Collaborative Parent Studies for HIV Treatment
- Plain-language title
- Continued Access to HIV Treatment for People Finishing Earlier ViiV Healthcare StudiesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 13 November 2026